ASSESSMENT OF THE CLINICAL IMPACT OF AMBLYOPIA PATCHING THERAPY IN PATIENTS WITH DOWN SYNDROME
Genetics and Molecular Research · 05.10.2026
DOI: 10.4238/tsjvhw21 ↗Kurz gefasst
Fachartikel in der Zeitschrift Genetics and Molecular Research, online erschienen am 05.10.2026. Verfasst von Muhammad Zubair Nazar und 9 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-SA 4.0).
Abstract (Originalsprache)
Down syndrome (trisomy 21) is accompanied by a high burden of eye disease, and amblyopia is one of the few problems that can be treated if it is found. Evidence for patching in this group is thin, because most trials leave out children with intellectual disability. We assessed the clinical impact of part-time occlusion therapy in children and adolescents with Down syndrome and amblyopia. In this prospective longitudinal study at the Strabismus Unit of Myo hospital, Lahore, Pakistan (September 2024 to May 2025), 30 patients aged 8-18 years were enrolled (18 aged 8-12 years; 18 male). After refraction, the better eye was patched for 4 h/day, 5 days/week, together with 2 h/day of near visual activities. Best-corrected visual acuity (logMAR) and refractive prescription were recorded at baseline, 1 month and 3 months and analyzed by repeated-measures ANOVA with Greenhouse-Geisser correction and pairwise comparisons. Twenty patients were hypermetropic and 10 were myopic. Mean logMAR acuity changed from 0.55 ± 0.27 at baseline to 0.54 ± 0.27 at 1 month and 0.41 ± 0.26 at 3 months (P = 0.041). The change was not significant at 1 month (mean difference 0.010, P = 0.249) but was significant at 3 months (0.142 logMAR, 95%CI 0.049-0.234, P = 0.002), about 1.4 chart lines. The mean recorded refractive prescription also decreased, from 2.13 D at baseline to 1.72 D at 3 months (P = 0.047). Poor attendance and limited cooperation were the main practical difficulties. Patching combined with refractive correction and near activities was followed by a measurable gain in visual acuity within three months, with the benefit appearing after the first month. Because there was no control group, part of the change may reflect refractive adaptation and practice effects, and larger controlled studies with longer follow-up are needed.
Zitieren
APA
Nazar, M. Z., Jan, U. U., Mughal, D. S., Saleem, A., Salam, Z., Huzaifa, M., Gillani, P. A. U. A., Asif, T., Ahmar, M. A., & Ahmad, M. (2026). ASSESSMENT OF THE CLINICAL IMPACT OF AMBLYOPIA PATCHING THERAPY IN PATIENTS WITH DOWN SYNDROME. Genetics and Molecular Research. https://doi.org/10.4238/tsjvhw21
Vancouver
Nazar MZ, Jan UU, Mughal DS, Saleem A, Salam Z, Huzaifa M, et al. ASSESSMENT OF THE CLINICAL IMPACT OF AMBLYOPIA PATCHING THERAPY IN PATIENTS WITH DOWN SYNDROME. Genetics and Molecular Research. 2026. doi:10.4238/tsjvhw21
BibTeX
@article{Nazar2026,
author = {Nazar, Muhammad Zubair and Jan, Ubaid Ullah and Mughal, Dr Summan and Saleem, Ayesha and Salam, Zainab and Huzaifa, Muhammad and Gillani, Prof.Syed Asad Ullah Arsalan and Asif, Tooba and Ahmar, Muhammad Ans and Ahmad, Muhammad},
title = {ASSESSMENT OF THE CLINICAL IMPACT OF AMBLYOPIA PATCHING THERAPY IN PATIENTS WITH DOWN SYNDROME},
journal = {Genetics and Molecular Research},
year = {2026},
doi = {10.4238/tsjvhw21}
}
EUVIMED